Fundraising rounds for health startups are taking longer to close and investors are doing more due diligence, said Ulili Onovakpuri, managing partner of Kapor Capital, during a Monday panel at the MedCity INVEST conference in Chicago.
There are too many flaws in AI for it to replace physicians, execs said during a Monday panel at the MedCity INVEST conference in Chicago. Instead, it should be used to make physicians' work easier.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
When it comes to her feelings about investing in care delivery startups, it’s a real “mixed bag” for Ulili Onovakpuri, managing partner at Kapor Capital. This is because a lot of them operate on a cash-pay model. She summarized the issue quite succinctly: there’s an incredible amount of innovation happening, but the people who could benefit the most from this type of care will be the last ones to receive it.
Hear from patients, leading provider and payer executives, investors, and healthcare startups about how to improve the patient experience at the event, which kicks off the first day of the HLTH conference. ENGAGE at HLTH is scheduled for November 13 at the Venetian Expo in Las Vegas.